Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	75.22	83.16	61.9	173.31	183.35
Short-Term Investments	217.26	365.54	455.42	283.99	644.56
Cash & Short-Term Investments	292.48	448.7	517.32	457.3	827.91
Cash Growth	-34.82%	-13.26%	13.12%	-44.76%	56.05%
Other Receivables	1.9	1.7	3.3	6	6.6
Receivables	1.9	1.7	3.3	6	6.6
Prepaid Expenses	9.01	8.72	8.2	8.02	10.62
Total Current Assets	303.39	459.12	528.82	471.32	845.13
Property, Plant & Equipment	131.26	163.18	196.43	181.02	160.14
Long-Term Investments	80.67	3.65	79.47	370.18	207.95
Other Long-Term Assets	33.39	16.9	16.86	16.11	14.62
Total Assets	548.71	642.84	821.58	1,039	1,228
Accounts Payable	5.39	5.9	13.89	10.26	10.39
Accrued Expenses	21.55	21.98	29.73	29.65	29.83
Current Portion of Leases	7.51	6.78	6	3.2	2.97
Current Unearned Revenue	-	0.09	0.1	0.42	38.99
Other Current Liabilities	1.07	2.34	4.02	4.65	12.13
Total Current Liabilities	35.52	37.08	53.73	48.17	94.32
Long-Term Leases	83.25	88.35	95.12	69.93	50.81
Other Long-Term Liabilities	7.76	5.18	5.85	4.13	3.08
Total Liabilities	126.53	130.6	154.7	122.23	148.21
Common Stock	0.21	0.17	0.14	0.14	0.14
Additional Paid-In Capital	2,242	2,075	1,912	1,822	1,726
Retained Earnings	-1,820	-1,562	-1,235	-903.35	-646.34
Comprehensive Income & Other	-0.09	-0.96	-9.93	-2.57	0.27
Shareholders' Equity	422.18	512.23	666.88	916.41	1,080
Total Liabilities & Equity	548.71	642.84	821.58	1,039	1,228
Total Debt	90.76	95.12	101.12	73.13	53.78
Net Cash (Debt)	201.72	353.58	416.2	384.17	774.13
Net Cash Growth	-42.95%	-15.05%	8.34%	-50.37%	62.12%
Net Cash Per Share	1.04	2.25	2.91	2.83	6.43
Filing Date Shares Outstanding	217.26	169.09	144.5	142.75	140.65
Total Common Shares Outstanding	212.21	168.64	144.44	142.62	140.47
Working Capital	267.86	422.04	475.1	423.15	750.81
Book Value Per Share	1.99	3.04	4.62	6.43	7.69
Tangible Book Value	422.18	512.23	666.88	916.41	1,080
Tangible Book Value Per Share	1.99	3.04	4.62	6.43	7.69
Machinery	40.47	41.94	41.15	37.96	31.29
Construction In Progress	-	-	0.03	0.04	68.94
Leasehold Improvements	108.13	108.62	108.55	108.35	31.52

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q